Suppliers and packagers for generic pharmaceutical drug: PROPYLTHIOURACIL

PROPYLTHIOURACIL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Elizabeth	PROPYLTHIOURACIL	propylthiouracil	TABLET;ORAL	080172	ANDA	Actavis Pharma, Inc.	0228-2348-10	100 TABLET in 1 BOTTLE (0228-2348-10)	2006-01-15
Actavis Elizabeth	PROPYLTHIOURACIL	propylthiouracil	TABLET;ORAL	080172	ANDA	Teva Pharmaceuticals, Inc.	0480-9242-01	100 TABLET in 1 BOTTLE (0480-9242-01)	2024-07-10
Chartwell Molecular	PROPYLTHIOURACIL	propylthiouracil	TABLET;ORAL	080016	ANDA	Chartwell RX, LLC	62135-606-90	90 TABLET in 1 BOTTLE (62135-606-90)	1982-01-01

Propylthiouracil Suppliers and Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supplier landscape for propylthiouracil (PTU), a critical medication used to treat hyperthyroidism. The analysis details key manufacturers, production capacities, regulatory standing, and supply chain risks relevant to pharmaceutical companies and investors.

Who are the Primary Global Manufacturers of Propylthiouracil?

The production of propylthiouracil (PTU) is concentrated among a limited number of global manufacturers. These companies are primarily located in China and India, with a smaller presence in Europe. The active pharmaceutical ingredient (API) is produced by these entities and then supplied to drug formulators worldwide.

Key manufacturers include:

• China National Pharmaceutical Industry Corporation (Sinopharm): A major state-owned enterprise with a significant footprint in API production.
• Zhejiang NHU Company Ltd.: A prominent Chinese chemical and pharmaceutical manufacturer with established PTU production lines.
• LaoGong API (Group) Co., Ltd.: Another significant player in the Chinese API market.
• Divi’s Laboratories Limited: An Indian API manufacturer known for its large-scale production capabilities across various therapeutic areas, including antithyroid drugs.
• Dr. Reddy’s Laboratories: A major Indian pharmaceutical company with API manufacturing facilities.
• Wockhardt Limited: An Indian multinational pharmaceutical and biotechnology company that produces APIs.
• Sanofi: A French multinational pharmaceutical company that may source or manufacture PTU.

Data on specific production capacities for PTU from these manufacturers is often proprietary. However, market intelligence suggests that Chinese and Indian suppliers collectively account for the vast majority of global PTU API supply. For example, several Chinese chemical manufacturers have advertised PTU API with capacities ranging from kilograms to metric tons, indicating substantial scale.

What is the Regulatory Status and Compliance of PTU Suppliers?

Regulatory compliance is a critical factor for pharmaceutical companies sourcing PTU. Major regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others in different jurisdictions conduct inspections and maintain compliance records of API manufacturers.

Key regulatory considerations include:

• FDA Inspections and Warning Letters: Manufacturers supplying to the U.S. market are subject to FDA inspections. Recent FDA databases and publicly available inspection reports (e.g., through the FDA Establishment Registration & Drug Master File (DMF) system) are primary sources for assessing compliance. Companies found to be non-compliant may receive Warning Letters or import alerts, disrupting supply.
• EMA and European Pharmacopoeia (EP) Compliance: Suppliers for the European market must comply with EMA regulations and meet the quality standards outlined in the European Pharmacopoeia. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs) are often required.
• Good Manufacturing Practices (GMP): All reputable PTU suppliers must adhere to current Good Manufacturing Practices (cGMP). This involves robust quality management systems, process controls, and documentation.
• Drug Master Files (DMFs): Many API manufacturers file DMFs with regulatory authorities (e.g., FDA, Health Canada). A DMF provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Pharmaceutical companies can reference these DMFs in their drug applications.

Assessing the regulatory status requires reviewing public dockets, inspection reports, and the DMF status of potential suppliers. For instance, a review of FDA inspectional observations and warning letters issued to API manufacturers in China and India over the past five years would reveal specific compliance issues that could impact the availability of PTU. Specific to PTU, past shortages have sometimes been linked to quality control issues or plant shutdowns at key API manufacturers, highlighting the importance of continuous regulatory monitoring.

What are the Major Production Technologies and Quality Standards for PTU?

The synthesis of propylthiouracil (PTU) is a well-established chemical process. The primary route involves the reaction of ethyl 3-oxohexanoate with thiourea in the presence of a base. While the fundamental chemistry is consistent, manufacturers differentiate themselves through process optimization, impurity control, and adherence to pharmacopoeial standards.

Key production and quality aspects include:

• Chemical Synthesis Route: The standard synthesis is generally considered mature. Manufacturers focus on yield optimization, solvent recovery, and waste stream management. Innovations may involve greener chemistry approaches or more efficient catalytic systems, though these are less publicly disclosed for established APIs like PTU.
• Impurity Profiling: Stringent control of process-related impurities and degradation products is paramount. Pharmacopoeias (e.g., USP, EP, JP) set limits for known impurities. Manufacturers must demonstrate their ability to consistently produce PTU meeting these specifications. Analytical techniques such as High-Performance Liquid Chromatography (HPLC) are critical for impurity detection and quantification.
• Particle Size and Morphology: For solid dosage form manufacturing, particle size distribution and crystal morphology of the PTU API can influence downstream processing, such as blending uniformity and tablet dissolution rates. Manufacturers may offer PTU with specific physical characteristics tailored to customer needs.
• Pharmacopoeial Compliance: PTU API must conform to the specifications outlined in relevant pharmacopoeias, including:
  • United States Pharmacopoeia (USP): Sets standards for identity, strength, quality, and purity.
  • European Pharmacopoeia (EP): Similar standards applicable in Europe.
  • Japanese Pharmacopoeia (JP): Standards for the Japanese market.
  • Indian Pharmacopoeia (IP): Standards relevant for the Indian market.

Manufacturers typically provide a Certificate of Analysis (CoA) with each batch, detailing the results against these pharmacopoeial requirements. Consistent CoA data and a history of passing analytical tests are indicators of reliable quality.

What are the Current Market Dynamics and Potential Supply Chain Risks?

The market for propylthiouracil (PTU) API is characterized by a concentrated supplier base, which introduces specific supply chain dynamics and risks. Shortages have occurred historically, underscoring the fragility of the current supply ecosystem.

Key market dynamics and risks:

• Limited Supplier Pool: As noted, a few manufacturers dominate global production. This concentration means that any disruption at a major facility—due to regulatory action, natural disaster, geopolitical instability, or operational issues—can have a significant impact on global supply.
• Price Volatility: Dependence on a few suppliers can lead to price fluctuations. Changes in raw material costs, energy prices, or increased regulatory compliance burdens can be passed on to buyers. Conversely, increased competition or overcapacity could lead to price decreases.
• Lead Times and Inventory Management: Pharmaceutical companies must carefully manage lead times, which can be substantial given international shipping and potential production scheduling constraints. Maintaining adequate safety stock is often necessary to mitigate potential shortages.
• Geopolitical Factors: The concentration of production in specific regions, particularly China and India, exposes the supply chain to geopolitical risks. Trade disputes, export restrictions, or national policies affecting pharmaceutical ingredient production can disrupt availability.
• Regulatory Changes: New or revised regulatory requirements (e.g., stricter impurity limits, updated GMP standards) can necessitate process changes or capital investment by manufacturers, potentially leading to temporary supply interruptions or increased costs.
• Quality Control Incidents: Past shortages of PTU have been linked to quality control issues at manufacturing sites, leading to batch rejections or temporary shutdowns. The potential for such incidents remains a significant risk.
• Demand Fluctuations: While PTU is a mature product, changes in prescribing patterns, the introduction of alternative therapies, or unexpected increases in demand due to disease outbreaks (though less likely for PTU specifically) can strain existing supply capacities.

Analyzing import/export data from regions like China and India, as well as tracking industry news for reports of plant expansions, shutdowns, or regulatory actions related to PTU manufacturers, provides insight into potential supply disruptions. For example, examining the number of PTU DMF filings and their approval status can indicate market entry or exit by suppliers.

What are Strategies for Mitigating PTU Supply Chain Risks?

Given the concentrated supplier landscape and inherent risks associated with propylthiouracil (PTU) API procurement, pharmaceutical companies must implement robust mitigation strategies. These strategies focus on diversification, strong supplier relationships, and proactive risk assessment.

Key mitigation strategies include:

• Supplier Diversification:
  • Dual Sourcing: Identify and qualify at least two independent PTU API manufacturers, preferably located in different geographic regions. This reduces reliance on a single supplier or country.
  • Geographic Diversification: Beyond China and India, explore potential suppliers in other regions where regulatory oversight is strong and manufacturing capabilities exist, even if at a smaller scale or higher cost.
• Strategic Supplier Relationships:
  • Long-Term Contracts: Negotiate long-term supply agreements that include provisions for guaranteed volume, price stability, and clear change control processes.
  • Collaborative Forecasting: Share demand forecasts with key suppliers to enable better production planning and capacity allocation.
  • Regular Audits and Performance Monitoring: Conduct frequent quality and regulatory audits of all critical suppliers. Track key performance indicators (KPIs) such as on-time delivery, quality compliance, and responsiveness.
• Inventory Management and Buffer Stock:
  • Strategic Safety Stock: Maintain adequate levels of PTU API inventory at company-owned warehouses or through third-party logistics providers to buffer against unexpected supply interruptions. The optimal level should be determined by a risk-based assessment of potential lead times and disruption probabilities.
  • Consignment Stock: Explore options for consignment stock arrangements with key suppliers, where the API is held on-site but owned by the supplier until consumed.
• Regulatory Intelligence and Proactive Monitoring:
  • Continuous Regulatory Monitoring: Actively track regulatory changes, inspection reports, and warning letters issued by major health authorities concerning PTU manufacturers. Subscribe to regulatory intelligence services.
  • Early Warning Systems: Develop internal systems or utilize external services to identify potential supply chain disruptions based on news, geopolitical events, or supplier-specific information.
• Supply Chain Mapping and Transparency:
  • Tier-N Mapping: Understand the supply chain beyond the immediate API manufacturer, including critical raw material suppliers and key intermediates. Identify potential bottlenecks or single points of failure further upstream.
  • Transparency Initiatives: Encourage suppliers to be transparent about their own supply chain risks and contingency plans.
• Alternative Sourcing and Emergency Preparedness:
  • Pre-Qualification of Alternatives: Identify and, where feasible, pre-qualify alternative suppliers or manufacturing processes that could be activated in an emergency.
  • Contingency Planning: Develop detailed contingency plans for worst-case scenarios, including alternative logistics routes and expedited manufacturing options.

Implementing these strategies requires a dedicated supply chain management function with expertise in global sourcing, quality assurance, and regulatory affairs. The investment in diversification and robust supplier management is essential for ensuring the continuous availability of critical medicines like PTU.

Key Takeaways

• Global PTU API production is concentrated in China and India, with a limited number of dominant manufacturers.
• Regulatory compliance (FDA, EMA, cGMP) is a critical differentiator and a potential source of supply disruption.
• Quality standards are defined by pharmacopoeias (USP, EP, JP, IP), with impurity profiling and consistent CoA data being key indicators of reliability.
• Supply chain risks include supplier concentration, price volatility, geopolitical factors, and the potential for quality control incidents.
• Mitigation strategies involve supplier diversification, long-term contracts, strategic inventory management, and continuous regulatory and geopolitical monitoring.

Frequently Asked Questions

1. What is the current global production capacity for propylthiouracil API? Specific global production capacities are proprietary and not publicly disclosed. However, market analysis indicates sufficient aggregate capacity to meet global demand, contingent on uninterrupted operation of key manufacturing sites.

2. Are there any new entrants or emerging technologies in PTU API manufacturing? The market for PTU API is mature, with established synthesis routes. Significant investment in new entrants or disruptive technologies for this specific API is unlikely in the near term, given its status as a well-established generic drug.

3. How can I verify the GMP compliance of a PTU API supplier? Verification involves reviewing the supplier's GMP certificates, inspection reports from regulatory authorities (e.g., FDA EIRs, EMA inspection reports), and conducting on-site audits. Reviewing the supplier's history of FDA Form 483 observations and warning letters is also crucial.

4. What are the primary raw materials required for PTU synthesis, and are they subject to supply risks? Key raw materials include thiourea and derivatives of hexanoic acid. The supply chain for these upstream intermediates can also be subject to risks, though they are generally more widely produced than specialized APIs.

5. What is the typical shelf life of propylthiouracil API, and how does it impact inventory management? The typical shelf life for PTU API, when stored under recommended conditions, is usually two to five years. This allows for reasonable inventory holding periods, but requires adherence to proper storage and retesting protocols.

Citations

[1] United States Pharmacopeia. (n.d.). Propylthiouracil. In USP-NF. Retrieved from [USP website] [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [EDQM website] [3] U.S. Food and Drug Administration. (n.d.). Establishment Registration & Drug Master File (DMF). Retrieved from [FDA website] [4] (Various Proprietary Market Research Reports on Pharmaceutical API Supply Chains). (2022-2024). [5] (Publicly Available Regulatory Filings and Inspection Reports for API Manufacturers). (Ongoing).